Unidade Local De Saude Do Alto Ave E.P.E.
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Strahilevitz, Jacob
PETERPEN, NCT03671967: PipEracillin Tazobactam Versus MERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae

Recruiting
4
1084
Canada, RoW
Piperacillin/tazobactam, Meropenem
Rambam Health Care Campus, Rabin Medical Center, University of Modena and Reggio Emilia, Tel Aviv Medical Center, Meir Medical Center, Soroka University Medical Center, The Chaim Sheba Medical Center, McGill University Health Centre/Research Institute of the McGill University Health Centre, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Hadassah Medical Organization
Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia
01/26
04/26
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
NCT05304221: A Prospective Cluster-Randomized, Controlled Crossover Trial to Validate an Electronic "Resistance Calculator"

Recruiting
N/A
1500
RoW
Shamir Resistance Calculator
Dror MarChaim, MD, Hadassah Medical Organization
Sepsis
10/24
01/25
NCT05618457: Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration

Recruiting
N/A
151
RoW
Aminoglycoside dose adjustment
Hadassah Medical Organization
Aminoglycoside Dosing Based on PK/PD Characteristics
12/25
12/25
Weis, Anastasia
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
NCT02499601: CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)

Recruiting
N/A
10
RoW
CORolla™ TAA device
CorAssist Cadiovascular Ltd.
Diastolic Heart Failure, Diastolic Dysfunction
09/21
09/24
Hanya, Hodaya
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27
Davidov, Ilan
RESTORATiVE303, NCT06237452: VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting
3
852
Europe, Canada, US, RoW
VE303, Placebo
Vedanta Biosciences, Inc.
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
06/27
10/27

Download Options